Skip to main content

An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome

  • Helen L. A. Weatherly (a1), Susan C. Griffin (a1), Catriona Mc Daid (a1), Kate H. Durée (a1), Robert J. O. Davies (a2), John R. Stradling (a2), Marie E. Westwood (a1) and Mark J. Sculpher (a1)...
  • Please note a correction has been issued for this article.

Objectives: An important option for the medical treatment of obstructive sleep apnea-hypopnea syndrome (OSAHS) is continuous positive airway pressure (CPAP) during sleep. This study reports on the cost-effectiveness of CPAP compared with dental devices and lifestyle advice. The work was commissioned by the NHS HTA Programme to inform the National Institute of Health and Clinical Excellence's (NICE) appraisal of CPAP.

Methods: A Markov model compared the interventions over the expected patient lifetime. The primary measure of cost-effectiveness was the incremental cost per quality-adjusted life-year (QALY) gained. The QALY incorporated the impact of treatments on daytime sleepiness, blood pressure and health-related quality of life (HRQoL).

Results: On average, CPAP was associated with higher costs and QALYs compared with dental devices or lifestyle advice. In the base-case analysis, the incremental cost-effectiveness ratio (ICER) for CPAP compared with dental devices was around £4,000 per QALY (2005–06 prices). The probability that CPAP is more cost-effective than dental devices or lifestyle advice at a threshold value of £20,000 per QALY was 0.78 for men and 0.80 for women. Several sensitivity analyses were undertaken and it was found that the ICER for CPAP consistently fell below £20,000 per QALY gained, apart from in a subgroup with mild disease.

Conclusions: The model suggests that CPAP is cost-effective compared with dental devices and lifestyle advice for adults with moderate or severe symptomatic OSAHS at the cost-effectiveness thresholds used by NICE. This finding is reflected in the NICE guidance.

Hide All
1. Anderson, KM, Odell, PM, Wilson, PW, Kannel, WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121 (pt 2):293298.
2. Ayas, NT, FitzGerald, JM, Fleetham, JA, et al. Cost-effectiveness of continuous positive airway pressure therapy for moderate to severe obstructive sleep apnea/hypopnea. Arch Intern Med. 2006;166:977984.
3. Barbe, F, Sunyer, J, de la Pena, A, et al. Effect of continuous positive airway pressure on the risk of road accidents in sleep apnea patients. Respiration. 2007;74:4449.
4. Bravo Vergel, Y, Palmer, S, Asseburg, C, et al. Is primary angioplasty cost-effective in the UK? Results of a comprehensive decision analysis. Heart. 2007;93:12381243.
5. Brazier, J, Roberts, J, Deverill, M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271292.
6. Brazier, J, Usherwood, T, Harper, R, Thomas, K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol. 1998;51:11151128.
7. Briggs, A, Claxton, K, Sculpher, M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
8. Briggs, A, Mihaylova, B, Sculpher, M, et al. The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 2007;93:10811086.
9. Chakravorty, I, Cayton, RM, Szczepura, A. Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. Eur Respir J. 2002;20:12331238.
10. Chiang, CL. Introduction to stochastic processes in biostatistics. New York: John Wiley; 1968.
11. Chilcott, J, Clayton, E, Chada, N, et al. Nasal continuous positive airways pressure in the management of sleep apnoea. Leicester: Trent Institute for Health Services Research; 2000.
12. Currie, C, McEwan, P, Peters, J, Patel, TC, Dixon, S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): Descriptive analysis from the first 20,000 subjects. Value Health. 2005;8:581590.
13. Curtis, L, Netten, A. Unit costs of health and social care 2006. Accessed 6 June 2007.
14. Dolan, P, Gudex, C, Kind, P, Williams, A. The time trade-off method: Results from a general population study. Health Econ. 1996;5:141154.
15. Dennis, MS, Burn, JP, Sandercock, PA, et al. Long-term survival after first-ever stroke: The Oxfordshire Community Stroke. Stroke. 1993;24:796800.
16. Department of Health. NHS reference costs 2005. Accessed 31 May 2007.
17. Department of Transport. Highways economic note No.1. 2004. Accessed 9 May 2007.
18. Drummond, M, Sculpher, M, Torrance, G, O'Brien, BJ, Stoddart, GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
19. Edwards, MJ, Brickley, MR, Goodey, RD, Shepherd, JP. The cost, effectiveness and cost effectiveness of removal and retention of asymptomatic, disease free third molars. Br Dent J. 1999;187:380384.
20. Fenwick, E, Claxton, K, Sculpher, M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779789.
21. Jenkinson, C, Davies, RJ, Mullins, R, Stradling, JR. Long-term benefits in self-reported health status of nasal continuous positive airway pressure therapy for obstructive sleep apnoea. QJM. 2001;94:9599.
22. Jenkinson, C, Stradling, J, Petersen, S. Comparison of three measures of quality of life outcome in the evaluation of continuous positive airways pressure therapy for sleep apnoea. J Sleep Res. 1997;6:199204.
23. Jones, L, Griffin, S, Palmer, S, et al. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: A systematic review and economic evaluation The cost-effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Health Technol Assess. 2004;8:1210.
24. Mar, J, Rueda, JR, Duran-Cantolla, J, et al. The cost-effectiveness of nCPAP treatment in patients with moderate-to-severe obstructive sleep apnoea. Eur Respir J. 2003;21:515522.
25. McArdle, N, Devereux, G, Engleman, HM, Haidarnejad, H. Patterns of continuous positive airways pressure (CPAP) use at the Scottish National Sleep Centre. Thorax. 1997;52 (Suppl 6):S34.
26. Mc Daid, C, Griffin, S, Weatherly, H, et al. Continuous positive airway pressure for the treatment of obstructive sleep apnoea-hypopnoea syndrome: A systematic review and economic analysis. Health Technol Assess. In press.
27. Moyer, CA, Sonnad, SS, Garetz, SL, Helman, JI, Chervin, RD. Quality of life in obstructive sleep apnea: A systematic review of the literature. Sleep Med. 2001;2:477491.
28. , NICE. Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome. Quick Reference Guide. Technology appraisal guidance; no. 139. London: National Institute for Health and Clinical Excellence; 2008.
29. , NICE. Guide to the methods of technology appraisal. Report No.: NO515. London: National Institute for Health and Clinical Excellence; 2004.
30. Pepperell, JC, Ramdassingh-Dow, S, Crosthwaite, N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: A randomised parallel trial. Lancet. 2002;359:204210.
31. Resmed. Cost-effectiveness and cost-utility of using continuous positive airways pressure in the treatment of severe obstructive sleep apnoea/hypopnoea syndrome in the UK. Resmed submission for CPAP technology appraisal. Abingdon: ResMed (UK); 2007.
32. Rosengren, A, Wilhelmsen, L, Hagman, M, Wedel, H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: A 16-year follow-up of the Primary Prevention Study, Göteborg, Sweden. J Intern Med. 1998;244:495505.
33. Sassani, A, Findley, LJ, Kryger, M, et al. Reducing motor-vehicle collisions, costs, and fatalities by treating obstructive sleep apnea syndrome. Sleep. 2004;27:453458.
34. Smith, I, Lasserson, TJ, Wright, J. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006;19:CD003002.
35. Sullivan, PW, Ghushchyan, V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410420.
36. Sundaram, S, Bridgman, SA, Lim, J, Lasserson, TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev. 2005;19:CD001004.
37. Tousignant, P, Cosio, MG, Levy, RD, Groome, PA. Quality adjusted life years added by treatment of obstructive sleep apnea. Sleep. 1994;17:5260.
38. West, SD, Nicoll, DJ, Wallace, TM, Matthews, DR, Stradling, JR. The effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes [unpublished observation]. 2007.
39. van Hout, BA, Al, MJ, Gordon, GS, et al. Cost, effects and cost-effectiveness-ratios alongside a clinical trial. Health Econ. 1994;3:309319.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Type Description Title
Supplementary materials

Weatherly supplementary tables
Weatherly supplementary tables

 Word (74 KB)
74 KB


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed